Our study underscores the utility of CRISPR/Cas9 tagging with Nanoluc luciferase in identifying potential NRF2 activators, paving the way for potential NAFLD therapeutics. This evidence concerns the gene NFE2L2 and metabolic dysfunction-associated steatotic liver disease.